Rectal dosimetric analysis following prostate brachytherapy

International Journal of Radiation Oncology Biology Physics

Volumn 43, Issue 5, 1999, Pages 1021-1027

  Merrick, Gregory S ^a,b   Butler, Wayne M ^a   Dorsey, Anthony T ^a   Lief, Jonathan H ^a   Walbert, Holly L ^a   Blatt, Heather J ^a  

^a WHEELING HOSPITAL   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

103Pd; 125I; Complication; Prostate brachytherapy; Rectal dosimetry; Tolerance

Indexed keywords

IODINE 125;

ARTICLE; BRACHYTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; HUMAN; IMPLANTATION; MALE; PRIORITY JOURNAL; PROCTITIS; PROSTATE CARCINOMA; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION RESPONSE; RECTUM MUCOSA;

BRACHYTHERAPY; COHORT STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; PALLADIUM; PROCTITIS; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RADIATION TOLERANCE; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECTUM; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0032914092     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00486-6     Document Type: Article

References (23)

1. Blasko J.C., Ragde H., Schumacher D. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance. Endocuriether Hyperthermia Oncol. 3:1987;131-139.
2. Grimm P.D., Blasko J.C., Ragde H. Ultrasound guided transperineal implantation of iodine-125 and palladium-103 for the treatment of early stage prostate cancer. Atlas Urol Clin North Am. 2:1994;113-125.
3. Blasko J.C., Wallner K., Grimm P.D., et al. Prostate specific antigen based disease control following ultrasound guided iodine-125 implantation for state T1/T2 prostatic carcinoma. J Urol. 154:1995;1096-1099.
4. Wallner K., Roy J., Zelefsky M., et al. Short term freedom from disease progression after I-125 prostate implantation. Int J Radiat Oncol Biol Phys. 30:1994;405-409.
5. Wallner K., Roy J., Harrison L. Tumor control and morbidity following transperineal I-125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol. 14:1996;449-453.
6. Dattoli M., Wallner K., Sorace R., et al. Pd-103 brachytherapy and external beam radiation therapy for clinically localized high risk prostatic carcinoma. Int J Radiat Oncol Biol Phys. 35:1996;875-879.
7. Ragde H., Blasko J.C., Grimm P.D., et al. Interstitial I-125 radiation without adjuvant therapy in the treatment of clinically localized prostate cancer. Cancer. 80:1997;442-453.
8. Blasko J.C., Grimm P.D., Ragde H. Brachytherapy and organ preservation in the management of carcinoma of the prostate. Semin Radiat Oncol. 3:1993;240-249.
9. Blasko J.C., Ragde H., Cavanagh W., et al. Long term outcomes of external beam irradiation and I-125/Pd-103 brachytherapy boost for prostate cancer. Int J Radiat Oncol Biol Phys. 36:1996;198.
10. Critz F., Levinson K., Williams W., et al. Prostate specific antigen nadir of 0.5 ng/ml or less defines disease freedom for surgically staged men irradiated for prostate cancer. Urology. 49:1997;668-672.
11. Critz F., Levinson K., Williams W., et al. Prostate specific antigen nadir The optimum level after irradiation for prostate cancer . J Clin Oncol. 14:1996;2893-2900.
12. Albert P., Zeitlin S., Raboy A., et al. High dose combination radiotherapy in the treatment of carcinoma of the prostate - 410 consecutive patients. J Urol. 157:1997;290.
13. Beyer D., Priestley J. Biochemical disease free survival following I-125 prostate implantation. Int J Radiat Oncol Biol Phys. 37:1997;559-563.
14. Stone N., Stock R. Brachytherapy for prostate cancer Real-time 3 dimensional interactive seed implantation . Techniques Urol. 1:1995;72-80.
15. Stock R.G., Stone N.N., DeWyngaert J.K., et al. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate cancer. Cancer. 77:1996;2386-2392.
16. Wallner K., Roy J., Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 32:1995;465-471.
17. Willins J., Wallner K. CT based dosimetry for transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 39:1997;347-353.
18. Merrick G.S., Butler W.M., Dorsey A.T., et al. Prostatic conformal brachytherapy I-125/Pd-103 postoperative dosimetric analysis . Radiat Oncol Invest. 5:1997;305-313.
19. Prestidge B.R., Bice W.S., Prete J.J., et al. A dose volume analysis of permanent transperineal prostatic brachytherapy. Int J Radiat Oncol Biol Phys. 39:1997;289.
20. Waterman F.M., Yue N., Corn B.W., et al. Edema associated with I-125 or Pd-103 prostate brachytherapy and its effect on post-implant dosimetry An analysis based on serial CT acquisition . Int J Radiat Oncol Biol Phys. 39:(Suppl 2):1997;220.
21. Merrick G.S., Butler W.M., Dorsey A.T., et al. The influence of timing on the dosimetric analysis of transperineal ultrasound guided prostatic conformal brachytherapy. Radiat Oncol Invest. 6:1998;182-190.
22. Butler W.M., Dorsey A.T., Nelson K.R., et al. Quality assurance calibration of I-125 rapid strand in a sterile environment. Int J Radiat Oncol Biol Phys. 41:1998;217-222.
23. Li S., Boyer A., Lu Y., et al. Analysis of dose surface histogram and dose wall histogram for the rectum and bladder. Med Phys. 24:1997;1107-1116.